| 2932.99.39 | 00 | Benzointetrahydropyranyl ester; and Xanthen-9-one | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2932.99.90 | 10 | Glucosamine and its salts and esters | kg | | | |
| 2933.39.20 | 00 | p-Chloro-2-benzylpyridine; 4-Chloro-1-methylpiperidine hydrochloride; 1,4-Dimethyl-6-hydroxy-3-cyanopyrid-2-one; Di-(2,2,6,6-tetramethyl-4-hydroxy- piperidine)sebacate; 2-Methyl-5-ethylpyridine; 4-Phenylpropylpyridine; α-Phenylpyridylacetic acid, methyl ester; Picolinic acid; 2-Pyridinecarboxaldehyde; and 2,5-Pyridinedicarboxylic acid | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4￠/kg + 39.5% |
| 2933.41.00 | 00 | Compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2933.99.02 | 00 | 2-[4-[(6-Chloro-2-quinoxalinyl)oxy]phenoxy]- propionic acid, ethyl ester; and O,O-Dimethyl-S-[(4-oxo-1,2,3-benzotri- azin-3-(4H)-yl)methyl]phosphorodithioate | kg | Free | | 15.4￠/kg + 64.5% |
| 2933.99.08 | 00 | Acetoacetyl-5-aminobenzimidazolone; 3-(2H-Benzotriazol-2-yl)-5-(tert-butyl)-4- hydroxybenzene propanoic acid, C7-C9 branched or linear alkyl esters; 2-(2H-Benzotriazol-2-yl)-6-dodecyl-4- methyl phenol, in liquid form, branched and linear; and 1,3,3-Trimethyl-2-methyleneindoline | kg | Free | | 15.4￠/kg + 52% |
| 2933.99.55 | | Drugs primarily affecting the central nervous system: | | | | |
| 2934.20 | | Compounds containing in the structure a benzothiazole ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2934.30 | | Compounds containing in the structure a phenothiazine ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2934.99.03 | 00 | 2-Acetylbenzo(b)thiophene; 3-Methylene-7-(2-phenoxyacetamido)- cephan-4-carboxylic acid, p-nitrobenzyl ester, 1-oxide; and Naphth[1,2-d]-[1,2,3]-oxadiazole-5-sulfonic acid and its sodium salt | kg | Free | | 15.4￠/kg + 52% |
| 2937.21.00 | | Steroidal hormones, their derivatives and structural analogues: | | | | |
| 2937.23.10 | 20 | Progesterone | kg | | | |
| 2937.23.50 | 20 | Progesterone | g | | | |
| 2937.29.90 | 10 | Salts and esters of cortisone | g | | | |
| 2937.29.90 | 20 | Salts and esters of hydrocortisone | g | | | |
| 2937.29.90 | 30 | Salts and esters of prednisone | g | | | |
| 2937.29.90 | 40 | Salts and esters of prednisolone | g | | | |
| 2938 | | XII. GLYCOSIDES AND VEGETABLE ALKALOIDS, NATURAL OR REPRODUCED BY SYNTHESIS, AND THEIR SALTS, ETHERS, ESTERS AND OTHER DERIVATIVES | | | | |
| 2938 | | Glycosides, natural or reproduced by synthesis, and their salts, ethers, esters and other derivatives: | | | | |
| 2939 | | Vegetable alkaloids, natural or reproduced by synthesis, and their salts, ethers, esters and other derivatives: | | | | |
| 2939.91.00 | 00 | Cocaine, ecgonine, levometamfetamine, metamfetamine (INN), metamfetamine racemate; salts, esters and other derivatives thereof | kg | Free | | 25% |
| 2940..00 | | Sugars, chemically pure, other than sucrose, lactose, maltose, glucose and fructose; sugar ethers, sugar acetals and sugar esters, and their salts, other than products of heading 2937, 2938 or 2939: | | | | |
| 3004 | | Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale: | | | | |
| 3004.32.00 | 00 | Containing corticosteroid hormones, their derivatives or structural analogues | kg | Free | | 25% |
| 3004.40.00 | 20 | Medicaments primarily affecting the central nervous system: | | | | |
